dc.creator | Sakkas L.I., Bogdanos D.P., Boumpas D., Mamouris Z., Gkoutzourelas A., Mavropoulos A., Tsouris Z., Liossis S.-N., Daoussis D., Vasilopoulos D., Tektonidou M., Tzioufas A., Efthymiou G., Dardiotis E., Kitas G., Sharif K., Blank M., Karussis D., Rimar D., Slobodin G., Porat-Katz B.-S., Vadasz Z., Amital H., Toubi E., Shoenfeld Y. | en |
dc.date.accessioned | 2023-01-31T09:53:17Z | |
dc.date.available | 2023-01-31T09:53:17Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 15651088 | |
dc.identifier.uri | http://hdl.handle.net/11615/78724 | |
dc.description.abstract | [No abstract available] | en |
dc.language.iso | en | en |
dc.source | Israel Medical Association Journal | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065409288&partnerID=40&md5=5383b772e855a3039b6fa01621ab749a | |
dc.subject | autoantibody | en |
dc.subject | curcumin | en |
dc.subject | dickkopf 1 protein | en |
dc.subject | hemosiderin | en |
dc.subject | HLA antigen | en |
dc.subject | hydroxychloroquine | en |
dc.subject | interleukin 10 | en |
dc.subject | levothyroxine | en |
dc.subject | methotrexate | en |
dc.subject | non receptor protein tyrosine phosphatase | en |
dc.subject | rituximab | en |
dc.subject | semaphorin 3A | en |
dc.subject | tuftsin | en |
dc.subject | complement component C3 | en |
dc.subject | curcumin | en |
dc.subject | gamma interferon | en |
dc.subject | hydroxychloroquine | en |
dc.subject | interleukin 17 | en |
dc.subject | levothyroxine | en |
dc.subject | methotrexate | en |
dc.subject | monoclonal antibody | en |
dc.subject | non receptor protein tyrosine phosphatase 13 | en |
dc.subject | rituximab | en |
dc.subject | adjuvant therapy | en |
dc.subject | Akt/mTOR signaling | en |
dc.subject | allele | en |
dc.subject | antibody response | en |
dc.subject | antiphospholipid syndrome | en |
dc.subject | autoimmune disease | en |
dc.subject | autoimmunity | en |
dc.subject | autophagy | en |
dc.subject | Bacteroidaceae | en |
dc.subject | cardiovascular disease | en |
dc.subject | cardiovascular risk | en |
dc.subject | coffee | en |
dc.subject | dietary supplement | en |
dc.subject | disease severity | en |
dc.subject | down regulation | en |
dc.subject | gene expression | en |
dc.subject | genetic analysis | en |
dc.subject | Hashimoto disease | en |
dc.subject | humoral immune deficiency | en |
dc.subject | hypocomplementemia | en |
dc.subject | immune dysregulation | en |
dc.subject | immunoreactivity | en |
dc.subject | immunosenescence | en |
dc.subject | knowledge | en |
dc.subject | microbiome | en |
dc.subject | multiple sclerosis | en |
dc.subject | Note | en |
dc.subject | pathogenesis | en |
dc.subject | Prevotellaceae | en |
dc.subject | primary sclerosing cholangitis | en |
dc.subject | psoriasis | en |
dc.subject | psoriatic arthritis | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | rheumatology | en |
dc.subject | vasculitis | en |
dc.subject | autoimmune disease | en |
dc.subject | clinical observation | en |
dc.subject | clinical study | en |
dc.subject | diagnosis | en |
dc.subject | Greece | en |
dc.subject | group process | en |
dc.subject | human | en |
dc.subject | Israel | en |
dc.subject | B cell lymphoma | en |
dc.subject | B cell maturation | en |
dc.subject | cell activation | en |
dc.subject | cell production | en |
dc.subject | cognitive defect | en |
dc.subject | complement activation | en |
dc.subject | Conference Paper | en |
dc.subject | disease activity | en |
dc.subject | fatigue | en |
dc.subject | genetic variability | en |
dc.subject | giant cell arteritis | en |
dc.subject | immaturity | en |
dc.subject | immune response | en |
dc.subject | lupus erythematosus nephritis | en |
dc.subject | lymphadenopathy | en |
dc.subject | peripheral blood mononuclear cell | en |
dc.subject | prevalence | en |
dc.subject | risk factor | en |
dc.subject | sarcoidosis | en |
dc.subject | signal transduction | en |
dc.subject | systemic sclerosis | en |
dc.subject | upregulation | en |
dc.subject | Autoimmune Diseases | en |
dc.subject | Autoimmunity | en |
dc.subject | Greece | en |
dc.subject | Group Processes | en |
dc.subject | Humans | en |
dc.subject | Israel | en |
dc.subject | Rheumatology | en |
dc.subject | Israel Medical Association | en |
dc.title | The second greek–israeli symposium on autoimmunity and rheumatology: Success through synergy | en |
dc.type | other | en |